A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

NCT03512197 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

511

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Midostaurin
DRUG: Placebo
DRUG: Chemotherapy

Sponsor

Novartis Pharmaceuticals